Guidance and quality standards Awaiting development

Skip to filters Skip to results

Showing 251 to 300 of 308

Type: GuidanceRemove Type: Guidance filter

Guidance and quality standards awaiting development
Title	Type
Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]	Technology appraisal guidance
Teplizumab for delaying the onset of type 1 diabetes in people 8 years and over at risk of developing the condition [ID6259]	Technology appraisal guidance
Teprotumumab for treating thyroid eye disease ID 6432	Technology appraisal guidance
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps TS ID 11918	Technology appraisal guidance
The Sonata Treatment - Transcervical Radiofrequency Fibroid Ablation using Intrauterine Ultrasound	Medical technologies guidance
Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915 ]	Technology appraisal guidance
Timrepigene emparvovec for treating choroideremia [ID3916]	Technology appraisal guidance
Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer TS ID 11951	Technology appraisal guidance
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]	Technology appraisal guidance
Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation TS ID 11841	Technology appraisal guidance
Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]	Technology appraisal guidance
Tiratricol for treating Allan–Herndon–Dudley syndrome TS ID 11794	Technology appraisal guidance
Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683	Technology appraisal guidance
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID 5077]	Technology appraisal guidance
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]	Technology appraisal guidance
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]	Technology appraisal guidance
Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]	Technology appraisal guidance
Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer TS ID 10693	Technology appraisal guidance
Tocilizumab for treating systemic sclerosis (ID1396)	Technology appraisal guidance
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]	Technology appraisal guidance
Tolebrutinib for treating relapsing multiple sclerosis TS ID 11845	Technology appraisal guidance
Toripalimab with chemotherapy for treating advanced oesophageal squamous cell cancer without previous systemic chemotherapy [ID6414]	Technology appraisal guidance
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]	Technology appraisal guidance
Transperineal laser ablation (TPLA) for treating lower urinary tract symptoms of benign prostatic hyperplasia using a ultra-micro invasive approach.	Interventional procedures guidance
Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive high-risk early breast cancer TS ID 11910	Technology appraisal guidance
Trastuzumab deruxtecan for treating HER2-mutated unresectable or metastatic non-squamous non-small-cell lung cancer after 1 or more therapies [ID3934]	Technology appraisal guidance
Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments [ID6226]	Technology appraisal guidance
Trastuzumab duocarmazine for treating HER2-positive unresectable metastatic breast cancer after 2 or more anti-HER2 treatments or after trastuzumab emtansine [ID6318]	Technology appraisal guidance
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]	Technology appraisal guidance
Treprostinil diethanolamine for treating pulmonary arterial hypertension TS ID 11772	Technology appraisal guidance
Triheptanoin for treating long-chain fatty acid oxidation disorders [ID3891]	Technology appraisal guidance
Troriluzole for spinocerebellar ataxia TS ID 12013	Technology appraisal guidance
Tucatinib with trastuzumab and pertuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]	Technology appraisal guidance
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together TS ID 11781	Technology appraisal guidance
Unilateral MRI-guided focused ultrasound thalamotomy for moderate-to-severe tremor in Parkinson's disease	Interventional procedures guidance
Upadacitinib for treating giant cell arteritis [ID6299]	Technology appraisal guidance
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]	Technology appraisal guidance
Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutation in the CFTR gene in people aged 6 years and over TS ID 11919	Technology appraisal guidance
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]	Technology appraisal guidance
Venglustat for treating gangliosidoses in people 2 years and over [ID6358]	Technology appraisal guidance
Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]	Technology appraisal guidance
Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer TS ID 11950	Technology appraisal guidance
Vilobelimab for treating COVID 19 TS ID 11815	Technology appraisal guidance
Virtual Wards for COPD exacerbations	Medical technologies guidance
Virtual Wards for Heart Failure	Medical technologies guidance
Vonicog alfa for preventing haemorrhage in people with von Willebrand disease when desmopressin is ineffective or not suitable TS ID 10266	Technology appraisal guidance
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over TS ID 11974	Technology appraisal guidance
Vosoritide for treating achondroplasia in children TSID 12001	Technology appraisal guidance
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]	Technology appraisal guidance
WP1048 for treating grass pollen allergy in people aged 18 to 60 TS ID 10467	Technology appraisal guidance

Results per page

10
25
50
All